Análisis coste-efectividad del tratamiento de la hepatitis C crónica con sofosbuvir-simeprevir en pacientes con genotipo 1 y fibrosis avanzada

Mar, Javier; Mar-Barrutia, Lorea; Gimeno-Ballester, Vicente; San Miguel, Ramón.
Med. clín (Ed. impr.) ; 146(2): 61-64, ene. 2016. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-147762

Documentos relacionados

  1. [CLINICAL AND ECONOMIC ANALYSIS OF ALTERNATIVE SCHEMES OF ANTIVIRAL THERAPY OF CHRONIC HEPATITIS C GENOTYPE 1 IN PATIENTS WHO DID NOT ANSWER TO THE PRIOR THERAPY, IN THE RUSSIAN FEDERATION].
  2. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
  3. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.
  4. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences.
  5. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
  6. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
  7. Economic impact of health resource optimisation in the approach to patients with hepatitis C.
  8. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.
  9. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals.
  10. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.